For instance, a Phase I single-arm trial (NCT05211315, n = 12) using NKG2D CAR-NK cells (derived from PBMC) in colorectal cancer resulted in only disease stabilization or minor tumor shrinkage, despite high ligand expression in the tumor samples. This evidence concerns the gene KLRK1 and colorectal cancer.